Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05209620
Other study ID # HNSZLYYNHL06
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 21, 2021
Est. completion date December 21, 2026

Study information

Verified date May 2023
Source Henan Cancer Hospital
Contact Zhihua Yao, M.D. Ph.D
Phone +8613592622292
Email zlyyyaozhihua1260@zzu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 21, 2026
Est. primary completion date December 21, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age between 18 to 75 years old (including 18 and 75) 2. Diagnosed as diffuse large B-cell lymphoma; Recurrence or progression of central nervous system disease confirmed by imaging ± tissue biopsy pathology or cerebrospinal fluid flow cytometry; Secondary central nervous system lymphoma can also be admitted when the systemic disease is well controlled 3. Having at least one measurable lesions 4. World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-2 ( ECOG 3 due to tumors can be included after being fully assessed by the investigator) 5. Life expectancy no less than 1 month 6. enough main organ function 7. Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study 8. Agreeing to sign the written informed consents Exclusion Criteria: 1. Poor peripheral disease control of secondary central nervous system lymphoma 2. Patients used pemetrexed or orelabrutinib in the past 3. Active malignant tumor need be treated at the same time 4. Other malignant tumor history 5. Serious surgery and trauma less than two weeks 6. Patients with active tuberculosis 7. Systemic therapy for serious acute/chronic infection 8. Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months 9. HIV-positive, AIDS patients and untreated active hepatitis 10. Patients with a history of deep vein thrombosis or pulmonary embolism less than 12 months 11. Patients with a history of mental illness or drug abuse 12. Poor compliance during the trial and/or follow-up phase 13. Allergies or people who are known to be allergic to any active ingredients, excipients, mouse-derived products or heterologous protein contained in this trial 14. Researchers determine unsuited to participate in this trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ICP-022
Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles). Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle).
Pemetrexed
Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).

Locations

Country Name City State
China Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary objective response rate the total proportion of patients with complete response (CR) and partial response (PR) every 6 weeks from the day of the first cycle of induction chemotherapy treatment (each cycle is 21 days) and every 8 weeks from the day of the first cycle of maintenance treatment to 5 years after last patient's enrollment (each cycle is 28 days)
Secondary progression-free survival the total proportion of patients with no progression from date of the first day of treatment to the date of confirmed progressive disease or death which one occurs first every 6 weeks from the day of the first cycle of induction chemotherapy treatment (each cycle is 21 days) and every 8 weeks from the day of the first cycle of maintenance treatment to 5 years after last patient's enrollment (each cycle is 28 days)
Secondary overall survival from date of first day of treatment to the date of death by any cause every 6 weeks from the day of the first cycle of induction chemotherapy treatment (each cycle is 21 days) and every 8 weeks from the day of the first cycle of maintenance treatment to 5 years after last patient's enrollment (each cycle is 28 days)
Secondary The incidence of grade 3-4 adverse events the incidence of grade 3 or 4 adverse events (based on NCI CTC-AE v5.0) up to 5 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516655 - A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients Phase 2
Recruiting NCT05054426 - Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL Phase 3
Recruiting NCT02623010 - Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Phase 2
Recruiting NCT04548648 - A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas Phase 2
Active, not recruiting NCT00293475 - Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Phase 1/Phase 2
Completed NCT03342586 - Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Terminated NCT02420795 - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Completed NCT01011920 - Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00967200 - Study of Tissue Samples From Patients With Glioma or Other Brain Tumors N/A
Recruiting NCT03684980 - LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma Early Phase 1
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT04938297 - Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma Phase 2
Recruiting NCT04792489 - DALY II USA/ MB-CART2019.1 for DLBCL Phase 2
Completed NCT01458730 - Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00153530 - Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Phase 4
Recruiting NCT04186520 - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT05816746 - Decitabine and Anti-PD-1 in R/R DLBCL Phase 2
Recruiting NCT06031194 - Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Active, not recruiting NCT03962127 - MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Completed NCT03690895 - Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy